CUL2: A Small Molecule Inhibitor of BCMA for CLL and FOL-L (G8453)

Target Name: CUL2

NCBI ID: G8453

CUL2

CUL2: A Small Molecule Inhibitor of BCMA for CLL and FOL-L

CUL2 (Cytokine Urealistinibil) is a drug candidate for the treatment of various diseases, including chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is a small molecule inhibitor of the B-cell maturation antigen (BCMA), which is a protein that is expressed in the cells of people with CLL and follicular lymphoma.

The BCMA protein is produced by the immune system and plays a critical role in the development and maintenance of these diseases. B-cell maturation antigens are a group of proteins that are expressed in the cells of people with B-cell lymphomas, including CLL and follicular lymphoma. The BCMA protein is one of these antigens and is expressed in the cells of people with CLL and follicular lymphoma.

The development and maintenance of CLL and follicular lymphoma is a complex process that involves the interplay of many different proteins and factors. One of the key factors in this process is the BCMA protein. The BCMA protein plays a critical role in the development and maintenance of these diseases by promoting the growth and survival of the cancer cells.

CUL2 is a small molecule inhibitor of the BCMA protein. It works by binding to the BCMA protein and inhibiting its activity. This inhibition leads to the collapse of the cancer cells, which can result in the death of the cancer cells and a reduction in the size of the tumors.

CUL2 is currently being tested as a potential drug candidate for the treatment of CLL and follicular lymphoma in clinical trials. These trials are designed to assess the safety and effectiveness of CUL2 in treating these diseases. If the results of these trials are positive, CUL2 could be approved for use as a new treatment for CLL and follicular lymphoma.

In addition to its potential use as a drug, CUL2 also has potential as a biomarker. The BCMA protein is a potential biomarker for the diagnosis and prognosis of CLL and follicular lymphoma. The levels of the BCMA protein are often reduced in the cells of people with CLL and follicular lymphoma, and these levels can be used as a marker for the disease.

CUL2 has also been shown to be effective in preclinical studies as a potential drug for the treatment of multiple myeloma, another type of cancer that is characterized by the production of multiple myeloma cells in the bone marrow. In these studies, CUL2 was shown to be effective in inhibiting the growth and survival of multiple myeloma cells.

Overall, CUL2 is a promising drug candidate for the treatment of CLL and follicular lymphoma. Its ability to inhibit the BCMA protein and its potential as a biomarker make it a promising agent for the treatment of these diseases. Further studies are needed to determine its safety and effectiveness in clinical trials.

Protein Name: Cullin 2

Functions: Core component of multiple cullin-RING-based ECS (ElonginB/C-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination of target proteins (PubMed:11384984, PubMed:26138980, PubMed:29779948, PubMed:29775578). CUL2 may serve as a rigid scaffold in the complex and may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme (PubMed:9122164, PubMed:10973499, PubMed:11384984, PubMed:12609982, PubMed:24076655). The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1 (PubMed:12609982, PubMed:24076655, PubMed:27565346). The functional specificity of the ECS complex depends on the substrate recognition component (PubMed:9122164, PubMed:10973499, PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS(VHL) mediates the ubiquitination of hypoxia-inducible factor (HIF) (PubMed:9122164, PubMed:10973499). A number of ECS complexes (containing either KLHDC2, KLHDC3, KLHDC10, APPBP2, FEM1A, FEM1B or FEM1C as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:26138980, PubMed:29779948, PubMed:29775578). ECS complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins (PubMed:27565346). ECS(LRR1) ubiquitinates MCM7 and promotes CMG replisome disassembly by VCP and chromatin extraction during S-phase (By similarity)

The "CUL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets